Scholarlink

<p>Due to the wide range of interstitial lung diseases (ILD) with varying prognoses, accurate diagnosis and identification of the underlying cause are essential in patients with ILD to enable targeted therapy. In approximately 50% of cases, an underlying cause can be identified [<CitationRef CitationID="CR1">1</CitationRef>]. Once the trigger has been successfully determined, avoidance or elimination of the causative agent represents the key therapeutic intervention. If no identifiable or removable cause can be found, or if exposure cessation alone does not lead to recovery, further treatment follows principles similar to those applied in ILDs of unknown etiology. In this context, distinguishing between inflammatory and fibrotic processes is often challenging [<CitationRef CitationID="CR2">2</CitationRef>]. Depending on the disease course, anti-inflammatory and/or antifibrotic therapy may be indicated [<CitationRef CitationID="CR3">3</CitationRef>].</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Was ist gesichert in der Therapie der interstitiellen Lungenerkrankungen?

  • 期刊论文

  • 发表日期：

    2025年10月15日

查看全文
  • Tobias Veit,
  • Jürgen Behr

摘要

Due to the wide range of interstitial lung diseases (ILD) with varying prognoses, accurate diagnosis and identification of the underlying cause are essential in patients with ILD to enable targeted therapy. In approximately 50% of cases, an underlying cause can be identified [1]. Once the trigger has been successfully determined, avoidance or elimination of the causative agent represents the key therapeutic intervention. If no identifiable or removable cause can be found, or if exposure cessation alone does not lead to recovery, further treatment follows principles similar to those applied in ILDs of unknown etiology. In this context, distinguishing between inflammatory and fibrotic processes is often challenging [2]. Depending on the disease course, anti-inflammatory and/or antifibrotic therapy may be indicated [3].